PURPOSE: Platinum resistance is a major limitation in the treatment of advanced non-small-cell lung cancer (NSCLC). Reduced intracellular drug accumulation is one of the most consistently identified features of platinum-resistant cell lines, but clinical data are limited. We assessed the effects of tissue platinum concentrations on response and survival in NSCLC. PATIENTS AND METHODS: We measured total platinum concentrations by flameless atomic absorption spectrophotometry in 44 archived fresh-frozen NSCLC specimens from patients who underwent surgical resection after neoadjuvant platinum-based chemotherapy. Tissue platinum concentration was correlated with percent reduction in tumor size on post- versus prechemotherapy computed tomography scans. The relationship between tissue platinum concentration and survival was assessed by univariate and multicovariate Cox proportional hazards regression model analysis and Kaplan-Meier analysis. RESULTS: Tissue platinum concentration correlated significantly with percent reduction in tumor size (P < .001). The same correlations were seen with cisplatin, carboplatin, and all histology subgroups. Furthermore, there was no significant impact of potential variables such as number of cycles and time lapse from last chemotherapy on platinum concentration. Patients with higher platinum concentration had longer time to recurrence (P = .034), progression-free survival (P = .018), and overall survival (P = .005) in the multicovariate Cox model analysis after adjusting for number of cycles. CONCLUSION: This clinical study established a relationship between tissue platinum concentration and response in NSCLC. It suggests that reduced platinum accumulation might be an important mechanism of platinum resistance in the clinical setting. Further studies investigating factors that modulate intracellular platinum concentration are warranted.
PURPOSE:Platinum resistance is a major limitation in the treatment of advanced non-small-cell lung cancer (NSCLC). Reduced intracellular drug accumulation is one of the most consistently identified features of platinum-resistant cell lines, but clinical data are limited. We assessed the effects of tissue platinum concentrations on response and survival in NSCLC. PATIENTS AND METHODS: We measured total platinum concentrations by flameless atomic absorption spectrophotometry in 44 archived fresh-frozen NSCLC specimens from patients who underwent surgical resection after neoadjuvant platinum-based chemotherapy. Tissue platinum concentration was correlated with percent reduction in tumor size on post- versus prechemotherapy computed tomography scans. The relationship between tissue platinum concentration and survival was assessed by univariate and multicovariate Cox proportional hazards regression model analysis and Kaplan-Meier analysis. RESULTS: Tissue platinum concentration correlated significantly with percent reduction in tumor size (P < .001). The same correlations were seen with cisplatin, carboplatin, and all histology subgroups. Furthermore, there was no significant impact of potential variables such as number of cycles and time lapse from last chemotherapy on platinum concentration. Patients with higher platinum concentration had longer time to recurrence (P = .034), progression-free survival (P = .018), and overall survival (P = .005) in the multicovariate Cox model analysis after adjusting for number of cycles. CONCLUSION: This clinical study established a relationship between tissue platinum concentration and response in NSCLC. It suggests that reduced platinum accumulation might be an important mechanism of platinum resistance in the clinical setting. Further studies investigating factors that modulate intracellular platinum concentration are warranted.
Authors: Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson Journal: N Engl J Med Date: 2002-01-10 Impact factor: 91.245
Authors: Q Li; J J Yu; C Mu; M K Yunmbam; D Slavsky; C L Cross; F Bostick-Bruton; E Reed Journal: Anticancer Res Date: 2000 Mar-Apr Impact factor: 2.480
Authors: Apar Pataer; Neda Kalhor; Arlene M Correa; Maria Gabriela Raso; Jeremy J Erasmus; Edward S Kim; Carmen Behrens; J Jack Lee; Jack A Roth; David J Stewart; Ara A Vaporciyan; Ignacio I Wistuba; Stephen G Swisher Journal: J Thorac Oncol Date: 2012-05 Impact factor: 15.609
Authors: C F Verschraegen; S Kumagai; R Davidson; B Feig; P Mansfield; S J Lee; D S Maclean; W Hu; A R Khokhar; Z H Siddik Journal: J Cancer Res Clin Oncol Date: 2003-08-29 Impact factor: 4.553
Authors: Alex R Menter; Nikki M Carroll; Lori C Sakoda; Thomas Delate; Mark C Hornbrook; Rakesh K Jain; Lawrence H Kushi; Virginia P Quinn; Debra P Ritzwoller Journal: Clin Lung Cancer Date: 2016-08-20 Impact factor: 4.785
Authors: Helen H W Chen; Wen-Chung Chen; Zhang-Dong Liang; Wen-Bin Tsai; Yan Long; Isamu Aiba; Siqing Fu; Russell Broaddus; Jinsong Liu; Lynn G Feun; Niramol Savaraj; Macus Tien Kuo Journal: Expert Opin Ther Targets Date: 2015-05-25 Impact factor: 6.902
Authors: Spyridon P Basourakos; Likun Li; Ana M Aparicio; Paul G Corn; Jeri Kim; Timothy C Thompson Journal: Curr Med Chem Date: 2017 Impact factor: 4.530
Authors: Xiaofei Chen; Jade Mims; Xiumei Huang; Naveen Singh; Edward Motea; Sarah M Planchon; Muhammad Beg; Allen W Tsang; Mercedes Porosnicu; Melissa L Kemp; David A Boothman; Cristina M Furdui Journal: Antioxid Redox Signal Date: 2017-12-20 Impact factor: 8.401
Authors: Si-Si Wang; Maike Zimmermann; Hongyong Zhang; Tzu-Yin Lin; Michael Malfatti; Kurt Haack; Kenneth W Turteltaub; George D Cimino; Ralph de Vere White; Chong-Xian Pan; Paul T Henderson Journal: Int J Cancer Date: 2017-05-15 Impact factor: 7.396